Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

United States ,Germany ,Italy ,Norfolk ,Virginia ,Milan ,Lombardia ,Munich ,Bayern ,Scintomics Gmb ,Markt Fleming ,Davide Gauden , ,Study Group ,Drug Administration ,Bracco Group ,Technical University Of Munich ,Virginia Oncology Associates ,Us Oncology Research ,Nuclear Medicine ,Earth Diagnostics ,Late Breaking Abstract ,Prostate Specific Membrane Antigen Targeted ,True Positive ,New Drug Application ,Chief Executive Officer ,Blue Earth ,Correct Detection Rate ,Efficacy Analysis Population ,Plenary Session ,Radiohybrid Prostate Specific Membrane Antigen ,Technical University ,Blue Earth Diagnostics ,Scintomics Gmbh ,Earth Diagnostic ,Bracco Imaging ,Interventional Radiology ,Cardiac Catheterization ,Magnetic Resonance Imaging ,Contrast Enhanced Ultrasound ,Blue Earth Therapeutics ,